New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.
List view / Grid view
Pfizer’s investigational C. difficile vaccine was shown to reduce the duration and severity of disease, but not prevent primary C. difficile infection.
New research demonstrates the potential of dual-detection impulsive vibrational spectroscopy (DIVS), an ultrafast Raman spectroscopy technique.
US FDA approval based on 98 percent response rate in multiple myeloma patients treated once with Carvykti (ciltacabtagene autoleucel, cilta-cel).
The EDQM will include Real-Time Remote Inspections (RTEMIS) as an integral part of its system for the supervision of manufacturers of active substances from 2022.
1 March 2022 | By
Serious about Making Pharmaceuticals? Attend the UK’s largest event dedicated to supporting the future of the pharmaceutical product life-cycle.
Brian Henry, Global Head of Drug Product Design at Pfizer, is the new Chair of the Medicines Manufacturing Industry Partnership (MMIP), a body representing the voice of medicines manufacturing in the UK.
USP is developing mRNA quality guidelines to support the development of innovative medicines and vaccines.
New funding for Clinical Research Facilities will boost delivery of first-in-human to early safety and efficacy trials across England.
Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.
Investing $700mn to establish a new site, Eli Lilly plans to fuel the development of genetic medicines through the company’s new Institute for Genetic Medicine.
Over 90 percent of β-thalassemia patients treated with Betibeglogene autotemcel (beti-cel) achieved transfusion independence lasting over a year.
The Common Standard for electronic product information (ePI) is intended to improve delivery of information to patients and healthcare providers.
The EFPIA has published 10 recommendations to ensure that procurement practices across the EU are effective and sustainable, delivering high quality medicines for patients, in the right quantities and at the right time.
A new framework for how the pharmaceutical industry will use health data for research and development of cutting-edge new medicines has opened for consultation.